Monday, 18 Jun 2018

You are here

The RheumNow Week in Review -30 March 2018

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on drug regulatory decisions, fenofibrate and gout, Still's disease, TB and infection rates, SpA and hidradenitis suppurativa, and predicting methotrexate non-responders.

  1.  FDA Arthritis Advisory Committee is scheduled to meet on April 23rd to discuss the NDA for Eli Lilly's JAK inhibitor - baricitinib in moderate to severe RA. Discussion will be around risk:benefit assessment, dose selection & the risk of venous thromboembolic events. https://t.co/dQ4AdYZyQx
  2. FDA grants Fast Track designation to nintedanib for Rx of systemic sclerosis with interstitial lung disease, for which there is no approved therapy. Pending are results from SENSCIS study -nintedanib over 52 weeks in SSc-ILD. https://t.co/CdnhvETtCZ 
  3. Although approved by FDA in May 2017, the EMA (CHMP) has rejected abaloparitide for treatment of postmenopausal osteoporosis, citing cardiac concerns, study conduct & its data on non-vertebral fracture prevention. https://t.co/vYE96VkiRY
  4. Large BSRBR study of Serious infections w/ biologics shows SI=5.51 per 100PY for all; tocilizumab was higher vs ETN (HR 1.22; 1.02 to 1.47) & certolizumab lower or equal to ETN. 30-day mortality following SI was 10.4% (95% CI 9.2% to 11.6%). https://t.co/h5BieShHpH
  5. TB in USA continues to decline, in 2017, there were 9,093 new cases TB = an incidence rate of 2.8 cases per 100,000. TB is 15 times higher among non–U.S.-born persons (compared to U.S.-born persons) https://t.co/Jj30Pv3CFW
  6. Survey of 442 Dutch axial SpA patients finds Hidradenitis suppurativa twice as common (9.1% vs 4.1%) in AxSpA - HS/AxSpA more likely female with higher ASAS & BASDAI scores w/ more dactylitis & enthesitis. https://t.co/yJeyIr5uiM
  7. Analysis of US hospitalizations from 7 states compared 28269 lupus w/ 13269 controls; SLE associated with 33% more postoperative renal complications &  27% greater in-hospital mortality, BUT no higher rate of cardiac complications https://t.co/e40HUEWzmY
  8. UK gen population database shows that statin use in gout patients was associated with a 16% lower risk of all-cause mortality (HR=0.84) & 7.7 fewer deaths per 1,000 PY; moreso in those without prior CV disease https://t.co/ZFpvSelo4d
  9. IL-37 is elevated in active adult-onset Still's disease and may be a biomarker of AOSD activity. IL-37 correlates with systemic score, IL-1β, IL-18, and IL-10. IL-37 is an antiiinflammatory cytokine that inhibits IL-18 activity. https://t.co/IFQrOpBKdi
  10. Anakinra May Attenuate Stroke Outcomes 
  11. Precision Genetics Can Predict Methotrexate Non-Responders    
  12. 2 Weeks Off Methotrexate OK for Flu Vaccine   
  13. FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

EULAR 2018 - Podcast from Day 3

This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.

Click HERE to listen.

You can also listen on iTunes, Soundcloud or Stitcher. 

The RheumNow Week in Review – EULAR18 Abbreviated (6.15.18)

We're crazy busy at EULAR all week.  Instead of this review, we recommend that you tune into our multiple podcasts from experts and faculty attending EULAR 2018 in Amsterdam.  You can find these on iTunes, SoundCloud or Stitcher.

Tune in next week for the EULAR week in review!

Changing my Mind at EULAR

Each year I attend I hope that I’m going to come across something that changes my practice and this year, I think I may have struck gold at a session on Giant Cell arteritis at EULAR in Amsterdam.

EULAR 2018 - Day 2 Report

Highlights from Day 2 of the EULAR meeting in Amsterdam include high MBDA scores in ACPA negative RA predicts remission; characterization of difficult RA; and gender differences in psoriatic responses to TNF inhibitors. 

EULAR 2018 - Podcast from Day 1 & 2

This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.